Published in Medical Letter on the CDC and FDA, July 23rd, 2006
The research and development on avian flu vaccine for humans is sponsored and supported by the Ministry of Science and Technology, and is co-developed by the Chinese Centers for Disease Control and Prevention (CDC) and Sinovac.
The preliminary results showed good immunogenicity, with a sero-positive rate of 78.3%, which exceeds the criteria for assessment of vaccines established by the Committee for Proprietary Medicinal Products of the European Union.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.